353 related articles for article (PubMed ID: 11154267)
1. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.
Foster JS; Henley DC; Bukovsky A; Seth P; Wimalasena J
Mol Cell Biol; 2001 Feb; 21(3):794-810. PubMed ID: 11154267
[TBL] [Abstract][Full Text] [Related]
2. Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes.
McConnell BB; Gregory FJ; Stott FJ; Hara E; Peters G
Mol Cell Biol; 1999 Mar; 19(3):1981-9. PubMed ID: 10022885
[TBL] [Abstract][Full Text] [Related]
3. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.
Prall OW; Sarcevic B; Musgrove EA; Watts CK; Sutherland RL
J Biol Chem; 1997 Apr; 272(16):10882-94. PubMed ID: 9099745
[TBL] [Abstract][Full Text] [Related]
4. Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells.
Sandhu C; Donovan J; Bhattacharya N; Stampfer M; Worland P; Slingerland J
Oncogene; 2000 Nov; 19(47):5314-23. PubMed ID: 11103932
[TBL] [Abstract][Full Text] [Related]
5. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.
Hsieh FF; Barnett LA; Green WF; Freedman K; Matushansky I; Skoultchi AI; Kelley LL
Blood; 2000 Oct; 96(8):2746-54. PubMed ID: 11023508
[TBL] [Abstract][Full Text] [Related]
6. Aryl hydrocarbon receptor-mediated antiestrogenicity in MCF-7 cells: modulation of hormone-induced cell cycle enzymes.
Wang W; Smith R; Safe S
Arch Biochem Biophys; 1998 Aug; 356(2):239-48. PubMed ID: 9705214
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
[TBL] [Abstract][Full Text] [Related]
8. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.
Reynisdóttir I; Polyak K; Iavarone A; Massagué J
Genes Dev; 1995 Aug; 9(15):1831-45. PubMed ID: 7649471
[TBL] [Abstract][Full Text] [Related]
9. CDK2 is a target for retinoic acid-mediated growth inhibition in MCF-7 human breast cancer cells.
Teixeira C; Pratt MA
Mol Endocrinol; 1997 Aug; 11(9):1191-202. PubMed ID: 9259311
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of cyclin-dependent kinase inactivation by progestins.
Musgrove EA; Swarbrick A; Lee CS; Cornish AL; Sutherland RL
Mol Cell Biol; 1998 Apr; 18(4):1812-25. PubMed ID: 9528753
[TBL] [Abstract][Full Text] [Related]
11. Removal of Cdk inhibitors through both sequestration and downregulation in zearalenone-treated MCF-7 breast cancer cells.
Ahamed S; Foster JS; Bukovsky A; Diehl JA; Wimalasena J
Mol Carcinog; 2002 May; 34(1):45-58. PubMed ID: 12112322
[TBL] [Abstract][Full Text] [Related]
12. Involvement of p21 and p27 in the regulation of CDK activity and cell cycle progression in the regenerating liver.
Albrecht JH; Poon RY; Ahonen CL; Rieland BM; Deng C; Crary GS
Oncogene; 1998 Apr; 16(16):2141-50. PubMed ID: 9572495
[TBL] [Abstract][Full Text] [Related]
13. Requirement of cyclin E-Cdk2 inhibition in p16(INK4a)-mediated growth suppression.
Jiang H; Chou HS; Zhu L
Mol Cell Biol; 1998 Sep; 18(9):5284-90. PubMed ID: 9710613
[TBL] [Abstract][Full Text] [Related]
14. Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor p16(INK4a).
Mitra J; Dai CY; Somasundaram K; El-Deiry WS; Satyamoorthy K; Herlyn M; Enders GH
Mol Cell Biol; 1999 May; 19(5):3916-28. PubMed ID: 10207115
[TBL] [Abstract][Full Text] [Related]
15. Complex mechanisms underlying impaired activation of Cdk4 and Cdk2 in replicative senescence: roles of p16, p21, and cyclin D1.
Morisaki H; Ando A; Nagata Y; Pereira-Smith O; Smith JR; Ikeda K; Nakanishi M
Exp Cell Res; 1999 Dec; 253(2):503-10. PubMed ID: 10585273
[TBL] [Abstract][Full Text] [Related]
16. A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence.
Carroll JS; Prall OW; Musgrove EA; Sutherland RL
J Biol Chem; 2000 Dec; 275(49):38221-9. PubMed ID: 10991938
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent kinase (cdk) inhibitors/cdk4/cdk2 complexes in early stages of mouse mammary preneoplasia.
Said TK; Moraes RC; Singh U; Kittrell FS; Medina D
Cell Growth Differ; 2001 Jun; 12(6):285-95. PubMed ID: 11432803
[TBL] [Abstract][Full Text] [Related]
18. Induction of G1 phase arrest in MCF human breast cancer cells by pentagalloylglucose through the down-regulation of CDK4 and CDK2 activities and up-regulation of the CDK inhibitors p27(Kip) and p21(Cip).
Chen WJ; Chang CY; Lin JK
Biochem Pharmacol; 2003 Jun; 65(11):1777-85. PubMed ID: 12781329
[TBL] [Abstract][Full Text] [Related]
19. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution.
Planas-Silva MD; Weinberg RA
Mol Cell Biol; 1997 Jul; 17(7):4059-69. PubMed ID: 9199341
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation.
Tanner FC; Boehm M; Akyürek LM; San H; Yang ZY; Tashiro J; Nabel GJ; Nabel EG
Circulation; 2000 May; 101(17):2022-5. PubMed ID: 10790340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
